Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Ischemic Stroke Clinical Trial

— RODIN  

Official title:

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05041010
• Other study ID #: Neu2000KWL-P03
• Status: Recruiting
• Phase: Phase 3
• Start date: December 25, 2021
• Est. completion date: January 2025

Study information

• Verified date: September 2021
• Source: GNT Pharma
• Contact: Chun San An
• Phone: 82-31-8005-9910
• Email: csan[@]gntpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment to remove clot within 12 hours following stroke onset. Neu2000KWL will be administered before endovascular treatment.

Description:

Neu2000 was designed as a multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+ -permeable glutamate receptor, and free radicals, two major routes of brain cell death in stroke. Neu2000 is a moderate NR2B-selective NMDA receptor antagonist and spin trapping molecule (=free radical scavenger or antioxidant). Therapeutic potential of Neu2000 has been well demonstrated in four animal models of stroke with better efficacy and therapeutic time windows than either NMDA receptor antagonist or anti-oxidant advanced to clinical trials. In human phase I studies of 165 healthy subjects conducted in the United States and China, Neu2000KWL showed promising safety profiles without any serious adverse events up to a single intravenous infusion of 6000 mg that is far beyond the therapeutic target dose determined in animal models of transient ischemic stroke. Very recently, acute endovascular recanalization therapy has been introduced as the new standard care of care in acute ischemic stroke. The present study is aimed to examine efficacy and safety of Neu2000KWL in acute ischemic stroke patients receiving endovascular thrombectomy within 12 hours of stroke onset. This is a randomized trial, with placebo comparison, of comparing functional outcome at week 12 after 10 times of administration for five days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 496
• Est. completion date: January 2025
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

The trial subjects should satisfy all the following criteria.

1. Adults=19 years

2. Patients who can start endovascular therapy within 12 hours after the symptomatic onset of Ischemic stroke.

3. NIHSS on screening time point = 8 points

4. Patients whose general condition was favorable enough to perform daily activities without the help of others one day prior to the ischemic stroke onset (a person with mRS 0 or 1)

5. Patients whose CTA or MRA confirmed internal carotid artery occlusion and M1 or M2 occlusion of the middle cerebral artery, that are the types of major cerebral artery occlusion that can cause acute cerebral infarction and are subject to endovascular therapy.

6. Patients with early ASPECTS point=4 (Noncontrast brain cross-section CT or Brain cross-section MRI diffusion weighted imaging)

7. Patients who spontaneously submitted a written informed consent to participation on this clinical study. Exclusion Criteria: A patient who meets any one of the conditions below cannot participate in the Clinical trial.

1. Patients who meet the following exclusion criteria on imaging of endovascular therapy ? Patients whose occlusion location that can cause an acute ischemic stroke in the CTA (CT angiography) image meets under the following conditions: A. Occlusion of bilateral large artery B. Simultaneous infiltration of anterior and posterior circulation

2. Patients who have contraindication to contrast media for brain imaging.

3. Patients who are receiving renal replacement therapy such as dialysis due to acute or terminal nephropathy at screening point.

4. Patients who were diagnosed with cancer or received cancer therapy within 6 months at screening or have recurrent or transitional cancer.

5. Patients have high body temperature of 38oC or more and need antibiotic therapy due to medical opinion of infectious disease at screening.

6. Patients who are having pharmacotherapy due to liver diseases such as hepatic cirrhosis, etc. at screening point.

7. Patients who are pregnant or lactating. However, only a woman who has no possibility of pregnancy can participate in this clinical research. Woman with child-bearing potential can be defined as the woman who has not had the clear menopause or who has not had surgical treatment that makes pregnancy impossible.

8. Patients who have participated in other clinical trial within past 6 months at the screening time as a base. However, in case of participation of observatory experiment, the patient can participate in this clinical trial.

9. Patients who are determined unsuitable for participation in this clinical trial due to other reasons

Related Conditions & MeSH terms

• Ischemic Stroke

Intervention

Drug:
• Neu2000KWL group
1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
• Placebo group
1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day

Locations

Country	Name	City	State
Korea, Republic of	Dong-A University Hospital	Busan
Korea, Republic of	Inje University Busan Paik Hospital	Busan
Korea, Republic of	Gyeongsang National University Hospital	Changwon
Korea, Republic of	Chungbuk National University Hospital	Cheongju-si
Korea, Republic of	Keimyung University Dongsan Medical Center	Daegu
Korea, Republic of	Kyungpook National University Hospital	Daegu
Korea, Republic of	Daejeon Eulji Medical Center, Eulji University	Daejeon
Korea, Republic of	Chonnam National University Hospital	Gwangju
Korea, Republic of	Chosun University Hospital	Gwangju
Korea, Republic of	Hallym University Dongtan Sacred Heart hospital	Hwaseong
Korea, Republic of	Wonkwang University Hospital	Iksan
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	Inha University Hospital	Incheon
Korea, Republic of	Jeju National University Hospital	Jeju
Korea, Republic of	Jeonbuk National University Hospital	Jeonju
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Ewha womans University Seoul Hospital	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Kyunghee University Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Ulsan University Hospital	Ulsan
Korea, Republic of	Yongin Severance Hospital	Yongin

Sponsors (1)

Lead Sponsor	Collaborator
GNT Pharma

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of adverse events and serious adverse events		day0~week12
Other	All mortality rate until 12 weeks		day0~week12
Primary	mRS score evaluated at 12 week after the first dose of drug (Nelonemdaz or Placebo).		week12
Secondary	Proportion of mRS 0-2 evaluated at week 5 and week 12 after the first dose of drug (Nelonemdaz or Placebo).		week5, week12
Secondary	mRS score evaluated at week 5 after the first dose of investigational drug (Nelonemdaz or Placebo).		week5
Secondary	Proportion of mRS 0 measured at week 5 and week 12 after the first dose of investigational drug (Nelonemdaz or Placebo).		week5, week12
Secondary	Proportion of NIHSS 0-4 evaluated within 24 hours (Within 72 hours if weekend is included), 5 week, 12 week after the last injection of drug. (Evaluating 43 points for deaths)		24hour(or 72hour), week5, week12
Secondary	Volume of Ischemic stroke based on brain MRI diffusion weighted imaging within 24 hours and at week 12. (If MRI is not available, reading will be performed based on CT scan.)		24hour, week12
Secondary	Proportion of Barthel Index=95 evaluated at week 5 and week 12		week5, week12
Secondary	Occurrence rate of Symptomatic intracranial hemorrhage (SICH) described and defined by this study occurring within 24 hours after the last injection	[Definition of Symptomatic intracranial hemorrhage (SICH)] In the case that brain imaging confirms intracranial hemorrhage with neurological deterioration. (NIHSS score=4 points) neurological deterioration. (NIHSS score=4 points)	24hour